Dirk Schadendorf 个人学术档案

引用次数

	总计	2019 年至今
引用	205902	126265
h 指数	177	142
i10 指数	893	671

26000

13000

6500

19500

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024708 794 870 1049 1067 1009 1078 1071 1100 1318 1609 2500 3845 5343 6667 8746 11022 12427 13786 17452 22509 25486 24752 23280 12520

开放获取的出版物数量

查看全部

260 篇文章

26 篇文章

可查看的文章

无法查看的文章

根据资助方的强制性开放获取政策

合著作者

Selma UgurelProfessor of Medicine, University of Duisburg-Essen在 uk-essen.de 的电子邮件经过验证
Paolo A. AsciertoIstituto Nazionale Tumori Fondazione "G. Pascale", Napoli, Italy在 istitutotumori.na.it 的电子邮件经过验证
Georgina V LongMelanoma Institute Australia, The University of Sydney and Royal North Shore Hospital在 sydney.edu.au 的电子邮件经过验证
Jochen Sven Utikal, MDProfessor for Dermatooncology, German Cancer Research Center and University Medical Center Mannheim在 dkfz.de 的电子邮件经过验证
James LarkinRoyal Marsden Hospital / Institute of Cancer Research, London, UK在 rmh.nhs.uk 的电子邮件经过验证
Helen GogasNational and Kapodistrian University of Athens在 med.uoa.gr 的电子邮件经过验证
Antoni RibasUCLA在 mednet.ucla.edu 的电子邮件经过验证
Thomas EigentlerDepartment of Dermatology, Venereology and Allergology, Charité Berlin在 charite.de 的电子邮件经过验证
Alexander EGGERMONTPrincess Maxima Center & University Medical Center Utrecht, Netherlands alexander.eggermont在 prinsesmaximacentrum.nl 的电子邮件经过验证
Victoria AtkinsonUniversity of Queensland, Princess Alexandra Hospital, Gallipoli Medical Research Foundation在 health.qld.gov.au 的电子邮件经过验证
Joachim DissemondUniversity Duisburg-Essen在 uk-essen.de 的电子邮件经过验证
Susanne HornPhD在 helmholtz-munich.de 的电子邮件经过验证
Richard KeffordMacquarie University在 mq.edu.au 的电子邮件经过验证
Stefan B. EichmüllerGerman Cancer Research Center (DKFZ)在 dkfz.de 的电子邮件经过验证
Titus J. BrinkerDigital Biomarkers for Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany在 DKFZ.de 的电子邮件经过验证
Blank cNetherlands Cancer Institute在 nki.nl 的电子邮件经过验证
Stephan GrabbeProfessor für Dermatologie, Universitaetsmedizin Mainz在 unimedizin-mainz.de 的电子邮件经过验证
Rajmohan MuraliMemorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
Rajiv KumarGerman Cancer Research Center在 dkfz.de 的电子邮件经过验证
Alexander EnkProfessor der Dermatologie在 med.uni-heidelberg.de 的电子邮件经过验证

关注

Dirk Schadendorf

Professor für Dermatologie, University Hospital Essen; University of Duisburg-Essen

在 uk-essen.de 的电子邮件经过验证

Cancer melanoma translational research dermatology


标题按引用次数排序按年份排序按标题排序	引用次数引用次数	年份
Improved survival with ipilimumab in patients with metastatic melanoma FS Hodi, SJ O'day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ... New England Journal of Medicine 363 (8), 711-723, 2010	17236	2010
Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011	9132	2011
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015	8038	2015
Nivolumab in previously untreated melanoma without BRAF mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015	6102	2015
The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018	4534	2018
Vaccination of melanoma patients with peptide-or tumorlysate-pulsed dendritic cells FO Nestle, S Alijagic, M Gilliet, Y Sun, S Grabbe, R Dummer, G Burg, ... Nature medicine 4 (3), 328-332, 1998	3889	1998
Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017	3617	2017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019	3162	2019
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016	3009	2016
A landscape of driver mutations in melanoma E Hodis, IR Watson, GV Kryukov, ST Arold, M Imielinski, JP Theurillat, ... Cell 150 (2), 251-263, 2012	2964	2012
Improved overall survival in melanoma with combined dabrafenib and trametinib C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ... New England Journal of Medicine 372 (1), 30-39, 2015	2927	2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ... Science 350 (6257), 207-211, 2015	2746	2015
Genomic classification of cutaneous melanoma R Akbani, KC Akdemir, B áArman Aksoy, M Albert, A Ally, SB Amin, ... Cell 161 (7), 1681-1696, 2015	2715	2015
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018	2701	2018
Improved survival with MEK inhibition in BRAF-mutated melanoma KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ... New England Journal of Medicine 367 (2), 107-114, 2012	2606	2012
Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018	2526	2018
Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma D Schadendorf, FS Hodi, C Robert, JS Weber, K Margolin, O Hamid, ... Journal of clinical oncology 33 (17), 1889-1894, 2015	2432	2015
Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018	2220	2018
TERT promoter mutations in familial and sporadic melanoma S Horn, A Figl, PS Rachakonda, C Fischer, A Sucker, A Gast, S Kadel, ... Science 339 (6122), 959-961, 2013	2076	2013
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018	2071	2018

系统目前无法执行此操作，请稍后再试。

文章 1–20

每年引用数

重复的引用

合并的引用

添加合著者合著作者

上传 PDF

关注此作者

引用次数

合著作者

引用